Cargando…
Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma
Bispecific T cell engagers (TCEs) are an emerging anti-cancer modality that redirects cytotoxic T cells to tumor cells expressing tumor-associated antigens (TAAs), thereby forming immune synapses to exert anti-tumor effects. Designing pharmacokinetically acceptable TCEs and optimizing their size pre...
Autores principales: | Yoneyama, Tomoki, Kim, Mi-Sook, Piatkov, Konstantin, Wang, Haiqing, Zhu, Andy Z. X. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328551/ https://www.ncbi.nlm.nih.gov/pubmed/35839267 http://dx.doi.org/10.1371/journal.pcbi.1009715 |
Ejemplares similares
-
Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021) -
Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen
por: Palmen, Breanna, et al.
Publicado: (2023) -
Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017) -
Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules
por: Dilchert, Janine, et al.
Publicado: (2022) -
Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
por: Hua, Gwen, et al.
Publicado: (2023)